摘要
目的探讨过氧化体增殖物激活型受体γ2基因多态性与2型糖尿病及早期动脉粥样硬化的关系。方法应用聚合酶链反应—限制性片长多态性检测大连地区汉族人2型糖尿病患者(包括动脉粥样硬化组和非动脉粥样硬化组)过氧化体增殖物激活型受体γ2基因外显子B的Pro12Ala变异。结果在动脉粥样硬化组、非动脉粥样硬化组及对照组中过氧化体增殖物激活型受体γ2基因Pro/Pro基因型频率分别为0.961、0.896及0.892,Pro/Ala分别为0.039、0.104及0.108,Ala/Ala均为0,过氧化体增殖物激活型受体γ2基因Pro12Ala变异在对照组和糖尿病组间以及非动脉粥样硬化组和动脉粥样硬化组间差异均无显著性(P=0.407,P=0.096)。结论过氧化体增殖物激活型受体γ2基因Pro12Ala变异与2型糖尿病及其早期动脉粥样硬化的发生无明显相关。
Aim To investigate the association of peroxisome proliferator activated receptor T2（PPART2） gene polymorphism with type 2 diabetes meUitus（T2DM） and early period atherosclercsis （As） in Han people of Dalian （Chinese. Methods The genotypes of Prol2Ala variant in PPARγ2 gene exon B were determined by polymerase chain reaction-restriction fragment length polymorphism （PCR-RFLP） assay in 202 T2DM patients（77 cases with As and 125 cases without As）and 102 control subjects. Results The genotype frequeneies in As group, non-As group and control group are 0 . 961, 0. 896 and 0 . 892 for Pro/Pro. Thegenotypefxequeneiesare0.039, 0.104 and 0.108 for Pro/Ala. All of them are 0 for Ala/Ala. The frequencies of Pro/Pro are not different between subjects in control group and diabetes（ P = 0.407 ）. There is no difference between diabetic patients without As and those with As （ P = 0.096）. In control group, subjects with Ala carrier have higher BMI than those with non-Ala carrier（ P = 0. 003 ）. Stepwise regression artaiysis shows PPARγ2-Pro12Ala is not an independent danger factor for BMI. In diabetic group, there is no association between PPARγ2 polymorphism and clinical characteristics. Conclusions PPARγ2 gene Pro12Ala polymorphism is not associated with the incidence of T2DM and early period As in Han people of Dalian Chinese. But subjects with Ala carrier have higher BMI than than with non-Ala cartier in control group.
出处
《中国动脉硬化杂志》
CAS
CSCD
2005年第5期604-606,共3页
Chinese Journal of Arteriosclerosis
基金
"十五"国家科技攻关课题(2001BA702B01)
辽宁省科技厅攻关项目(2002225003-6)
辽宁省教育厅课题(202203266)
